Celldex Therapeutics, Inc.
US ˙ NasdaqCM ˙ US15117B2025

SecurityCLDX / Celldex Therapeutics, Inc.
InstitutionONEQ - Fidelity Nasdaq Composite Index Tracking Stock
Latest Disclosed Ownership28,050 shares
Latest Disclosed Value $ 554,829
ONEQ - Fidelity Nasdaq Composite Index Tracking Stock reports 33.43% increase in ownership of CLDX / Celldex Therapeutics, Inc.

On July 24, 2025 - ONEQ - Fidelity Nasdaq Composite Index Tracking Stock filed a NPORT-P form disclosing ownership of 28,050 shares of Celldex Therapeutics, Inc. (US:CLDX) valued at $554,829 USD as of May 31, 2025. The entity filed a previous NPORT-P on April 25, 2025 disclosing 21,023 shares of Celldex Therapeutics, Inc.. This represents a change in shares of 33.43% during the quarter. The current value of the position is $802,791 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2025-07-24 2025-05-31 NP CELLDEX THERAPEUTICS EC US15117B2025 28,050 7,027 33.43 555 28.24 0.0073
2025-04-25 2025-02-28 NP CELLDEX THERAPEUTICS EC US15117B2025 21,023 540 2.64 432 -23.13 0.0058
2025-01-27 2024-11-30 NP CELLDEX THERAPEUTICS EC US15117B2025 20,483 -1,813 -8.13 562 -38.98 0.0076
2024-10-29 2024-08-31 NP CELLDEX THERAPEUTICS EC US15117B2025 22,296 3,245 17.03 921 45.27 0.0137
2024-07-26 2024-05-31 NP CELLDEX THERAPEUTICS EC US15117B2025 19,051 225 1.20 634 -29.87 0.0101
2024-04-24 2024-02-29 NP CELLDEX THERAPEUTICS EC US15117B2025 18,826 279 1.50 905 61.43 0.0151
2024-01-24 2023-11-30 NP CELLDEX THERAPEUTICS EC US15117B2025 18,547 -1,434 -7.18 560 0.54 0.0107
2023-10-27 2023-08-31 NP CELLDEX THERAPEUTICS EC US15117B2025 19,981 300 1.52 557 -10.88 0.0109
2023-07-26 2023-05-31 NP CELLDEX THERAPEUTICS EC US15117B2025 19,681 60 0.31 626 -25.51 0.0135
2023-04-27 2023-02-28 NP CELLDEX THERAPEUTICS EC US15117B2025 19,621 450 2.35 840 18.00 0.0205
2023-01-26 2022-11-30 NP CELLDEX THERAPEUTICS EC US15117B2025 19,171 470 2.51 711 25.18 0.0178
2022-10-26 2022-08-31 NP CELLDEX THERAPEUTICS EC US15117B2025 18,701 -9,566 -33.84 569 -14.46 0.0142
2022-07-29 2022-05-31 NP CELLDEX THERAPEUTICS EC US15117B2025 28,267 10,451 58.66 665 24.81 0.0169
2022-04-28 2022-02-28 NP CELLDEX THERAPEUTICS EC US15117B2025 17,816 17,816 533 0.0123
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.